Johnson & Johnson CEO Joaquin Duato said the company will seek opportunities to merge with or acquire companies that add value to its focus areas of eye care, surgical robots, orthopedics and cardiovascular products, Reuters’ Leroy Leo and Aditya Samal report. The company is in the process of spinning off its consumer healthcare unit under the brand Kenvue, the authors note. "We’ll continue to be disciplined in looking for opportunities in which we can create value that serve a significant unmet medical need like heart failure," Duato said at the J.P. Morgan Healthcare Conference. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JNJ:
- Short Report: Bad News Bears continue to claw Silvergate, Futu Holdings
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Alkermes reports interim award in arbitration proceedings with Janssen
- Fate Therapeutics double downgraded to Underperform at BofA
- Fate Therapeutics downgraded to Neutral from Outperform at Wedbush